Jordan’s Hikma Raises Full-Year Forecast As Strong Doxycycline Sales Lift Prospects
This article was originally published in PharmAsia News
Executive Summary
Hikma Pharmaceuticals PLC shrugged off turmoil in its core Middle East markets and reported strong first half sales growth, helping the company to lift full-year revenue growth guidance to around 20% from 13%. The result was lifted by a 10-fold increase in sales of antibiotic doxycycline and continued strong sales in core markets as well as the United States and Europe.